IP Library Granted Patent US 11,499,172
Granted Patent B2
US 11,499,172 · App. 16/630,297 · Granted Nov 15, 2022

Use of stereoselective transaminase in asymmetric synthesis of chiral amine

Inventors: Zhanbing Cheng (Shanghai, CN); Tao Zhang (Shanghai, CN); Zhenhua Tian (Shanghai, CN); Shaonan Ding (Shanghai, CN)
Assignee: Abiochem Biotechnology Co., Ltd.
C12P13/06C12N9/1096C12P13/001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,499,172
App. No.
16/630,297
Granted
Nov 15, 2022
Kind
B2
Abstract

Use of a stereoselective transaminase in the asymmetric synthesis of a chiral amine. In particular, provided is use of a polypeptide in the production of a chiral amine or a downstream product using a chiral amine as a precursor. Further provided is a method for producing a chiral amine, comprising culturing a strain expressing the polypeptide so as to obtain a chiral amine. Further provided are a chiral amine production strain and a method for constructing the chiral amine production strain. The stereoselective transaminase has a broad substrate spectrum and thus has a broad application potential in the preparation of a chiral amine.

Claims (18)

1. A method for producing a chiral amine, comprising:

(a) carrying out a reaction shown in equation Ito form a chiral amine in a liquid reaction system, using a prochiral carbonyl compound as a substrate, reacting the substrate with an amino donor in the presence of a prosthetic group and under the catalysis of a stereoselective transaminase; and

(b) isolating the chiral amine from the reaction system after carrying out the reaction in (a), wherein the stereoselective transaminase has an amino acid sequence having at least 90% sequence identity to the amino acid sequence shown in SEQ ID NO: 1; and

wherein the prochiral carbonyl compound comprises any one of compounds 6- 8, or a pharmaceutically acceptable salt thereof:

2. The method of claim 1 , wherein the chiral amine is used as a precursor for producing sitagliptin and the precursor is selected from group consisting of compound 6a, compound 7a, and compound 8a.

3. The method of claim 1 , wherein the chiral amine produced comprises any one of compounds 6a-8a or a pharmaceutically acceptable salt thereof:

4. The method according to claim 1 , wherein the amino donor comprises α-phenethylamine, β-aminobutyric acid, glycine, or isopropylamine.

5. The method according to claim 1 , wherein the prochiral carbonyl compound is selected from the group consisting of compounds 6-8,

and wherein the chiral amine produced is used as a precursor for producing sitagliptin.

6. A method for producing a chiral amine, comprising the steps of:

1) culturing a chiral amine producing Escherichia bacterial strain comprising a modification to express an R-selective-ω-transaminase having an amino acid sequence having at least 90% sequence identity to the amino acid sequence shown in SEQ ID NO: 1 under production conditions sufficient to induce the expression of the (R)-selective-ω-transaminase;

2) homogenizing and disrupting the cultured chiral amine producing Escherichia bacterial strain;

3) adding the disrupted cultured chiral amine producing Escherichia bacterial strain to a liquid reaction system comprising a prochiral carbonyl compound and an amino donor;

4) carrying out the reaction in the liquid reaction system to obtain the chiral amine; and

5) isolating the chiral amine from the liquid reaction system of 4); and

wherein the prochiral carbonyl compound comprises any one of compounds 6-8, or a pharmaceutically acceptable salt thereof:

7. The method for producing a chiral amine according to claim 6 , wherein the amino donor comprises α-phenethylamine, β-aminobutyric acid, glycine, or isopropylamine.

8. The method of claim 6 , wherein the modification to express an R-selective-ω-transaminase is expression of a full-length transaminase gene selected from the group consisting of a nucleotide sequence having at least 90% sequence identity to the sequence shown in SEQ ID NO: 2 and a complementary sequence thereof.

Assignments (2)
CHANGE OF NAME Recorded Jan 2, 2024
From: ABIOCHEM BIOTECHNOLOGY CO., LTD.
To: ABIOCHEM BIOTECHNOLOGY (GROUP) CO., LTD.
Reel/Frame 066162/0649 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2020
From: CHENG, ZHANBING; ZHANG, TAO; TIAN, ZHENHUA; QU, XUDONG; DING, SHAONAN
To: ABIOCHEM BIOTECHNOLOGY CO., LTD.
Reel/Frame 051499/0215 →
Priority Claims (1)
CN 201710561640.3 · Jul 11, 2017 · national
Continuity (1)
Related Publication 20200157587A1 · May 21, 2020
Cited By (1)
US 12,522,809